Friday, February 19, 2016 5:01:00 AM PDT | VentureDeal
Waltham, Massachusetts -- Biotechnology company Corvidia Therapeutics has received a commitment for $26 million in its first round of venture capital financing.
Corvidia says that it is developing next-generation cardiovascular therapies that leverage functional genomics to decode previously unrecognized genetic susceptibilities within cardiovascular populations. Lead investors in the round were Apple Tree Partners and Sofinnova Ventures. The company said it would use the funding to progress its COR-001 candidate into early clinical trials in 2016 and to advance its preclinical pipeline. Corvidia's CEO is Michael Davidson.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
